The global amino acid metabolism disorders treatment market revenue was valued at US$ 631.9 million in 2021 and is projected to reach US$ 962.8 million by 2031. The market is expected to grow at a CAGR (Compound Annual Growth Rate) of 4.3% from 2022 to 2031.

The amino acid metabolism is an important process that takes place in the human body to support a variety of biological responses. Tyrosinemia, Phenylketonuria, homocystinuria, non-ketotic,hyperglycinemia, and maple syrup urine illness are among the conditions that disrupt amino acid metabolism. These autosomal recessive conditions can be identified by examining the levels of amino acids in bodily fluids.

Factors Influencing Market Growth

Rise in the prevalence of diseases related to the metabolism of amino acids, including citrullinemia, phenylketonuria, and maple syrup urine illness high cost of medicines, increased research and development on remedies for abnormalities of amino acid metabolism. Such factors drive market growth.

Rise in healthcare expenditure provides amino acid metabolism disorders treatment opportunities for the market.


The increased price of amino acid supplements, ignorance about diseases of amino acid metabolism, and related side effects of phenylketonuria injections. Thus, these factors hamper market expansion.

COVID-19 Pandemic Effect on the Market Growth

The COVID-19 pandemic had a negative impact on pharmaceutical companies, which affected the treatment of problems with amino acids. This was brought on by the fall in demand for therapies for abnormalities of amino acid metabolism across several industries, including the pharmaceutical and healthcare industries. The government's substantial involvement in disease prevention efforts was the main reason for the interruptions it experienced.

Regional Analysis

North America had the largest market share for amino acid metabolism disorders therapy in 2021 and is anticipated to keep that position during the projected period. This is due to the rising demand for therapies for amino acid metabolism disorders, sapropterin, and Kuvan, Additionally, the developed healthcare system and accessibility of therapies fuels the market growth in this region. Disorders of amino acid metabolism are inherited metabolic conditions. When parents pass on to their offspring the faulty genes that cause these ailments, hereditary disorders are the result. The defective gene is typically carried by both parents of the affected kid in inherited metabolic diseases. Treatment of these disorders is accomplished with dietary restriction of the offending amino acid(s) and sometimes medication. Urea cycle disorders will require treatment with low-protein diets and medications to prevent hyperammonemia and remove toxic compounds.

Factors Affecting Market Growth
Prevalence of amino acid metabolism disorders such as maple syrup urine disease, phenylketonuria, and citrullinemia high cost of treatments, rise in research and development activities on amino acid metabolism disorders treatment are the factors driving the market
Increased disposable income in developing countries, and development of healthcare infrastructure are the factors driving the market.
An increase in healthcare expenditure offers an opportunity for the growth of the market.
The increase in the cost of amino acid supplements, lack of awareness of amino acid metabolism disorders, and associated side effects of phenylketonuria injections are hampering the market growth.
COVID-19 Pandemic Effect on the Market Growth
The COVID-19 pandemic had a negative impact on the pharmaceutical companies, which affected the treatment of problems of amino acid. This was brought on by the sharp fall in demand for therapies for abnormalities of amino acid metabolism across several industries, including the pharmaceutical and healthcare industries. The government's substantial involvement in disease prevention efforts was the main reason for the interruptions it experienced.

Regional Analysis
North America held the largest market share for amino acid metabolism disorders therapy in 2021 and is anticipated to keep that position during the projected period. This is due to the rising demand for therapies for amino acid metabolism disorders, sapropterin and Kuvan, Additionally, the developed healthcare system and accessibility of therapies help North America advance.
However, due to the rising frequency of amino acid metabolism disorders and the rise in patients seeking treatment for these illnesses, Asia-Pacific is anticipated to see the highest CAGR of during the market forecast period for treatments for amino acid metabolism disorders.

Leading Competitors
The leading competitors in the global amino acid metabolism disorders market are:
BioMarin Pharmaceutical Inc.
Teva Pharmaceutical Industries Ltd.
Merck KGaA
Pfizer Inc.
Recordati S.p.A.
Sanofi
Shine Star (Hubei) Biological Engineering Co.
AMINO GmbH
Civentichem LLC, Ltd.
GlaxoSmithKline PLC
Koninklijke DSM N.V.
Kyowa Hakko Kirin Co. Ltd.
Other Prominent Players

Segmentation Analysis
The global amino acid metabolism disorders treatment market segmentation focuses on Indication, Product, Distribution Cchannel, and Region.
Segmentation Based on Indication
Homocystinuria
Argininosuccinic aciduria
Phenylketonuria
Maple syrup urine disease
Citrullinemia
Segmentation Based on Product
Arginine
Thiamine
Folic Acid
Betaine
Vitamin B6 and B12
Sapropterin
Others
Segmentation Based on Distribution Cchannel
Online Providers
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Prescription type
Prescription drug
OTC drug
Segmentation Based on Region
North America
U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Europe

Asia-Pacific
China
India
Japan, South Korea
ASEAN
Rest of Asia-Pacific

Middle East & Africa (MEA)
Brazil
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America